DIABETES TECHNOLOGY SOCIETY (EIN 300012730) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2001

Legal Domicile

Principal Officer

DR DAVID C KLONOFF MD

Phone

6504919109

Tax Period

2025-01-01 to 2025-12-31

DIABETES TECHNOLOGY SOCIETY, founded in 2001, is a community nonprofit in the Diseases & Disorders sector that reported $1.0M in total revenue in fiscal year 2025. Revenue fell 47% from the prior year — a significant decline worth monitoring. Expenses of $1.6M exceeded revenue, resulting in a 57% operating deficit.

Mission

TO FACILITATE RESEARCH INTO THE TREATMENT, MONITORING, DIAGNOSIS AND PREVENTION OF DIABETES.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $191,000

Program Service Revenue $792,044

Investment Income $46,344

Other Revenue $0

TOTAL REVENUE $1,029,388

Expense Breakdown

Grants Paid $4,300

Salaries & Benefits $544,655

Fundraising Expenses $0

Program Expenses $1,401,081

Other Expenses $1,066,195

TOTAL EXPENSES $1,615,150

Year-over-Year Comparison

	2025	2024	Change
Revenue	$1,029,388	$1,925,694	-0.5%
Expenses	$1,615,150	$1,539,248	+0.0%
Net Income	$-585,762	$386,446	-2.5%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$306,747

Total Directors

$306,747

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
DR DAVID KLONOFF MD	PRESIDENT	40.00	Officer Director	$297,813	$8,934	$306,747
HENRY WYKOWSKI	DIRECTOR	1.00	Director	$0	$0	$0
AVERY DIAMOND	DIRECTOR	1.00	Director	$0	$0	$0
DR GERALD R SYDORAK MD	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$1,029,388	$1,615,150	$1,420,913	$-585,762
2024	$1,925,694	$1,539,248	$2,007,874	$386,446
2023	$1,379,124	$1,103,400	$1,611,702	$275,724
2022	$1,163,946	$1,267,548	$1,334,588	$-103,602
2021	$1,063,604	$891,137	$1,434,867	$172,467
2020	$922,975	$806,021	$1,261,104	$116,954
2019	$1,183,282	$1,323,809	$1,172,416	$-140,527
2018	$1,552,220	$1,267,395	$1,328,236	$284,825

DIABETES TECHNOLOGY SOCIETY